AI helps you reading Science

AI generates interpretation videos

AI extracts and analyses the key points of the paper to generate videos automatically


pub
Go Generating

AI Traceability

AI parses the academic lineage of this thesis


Master Reading Tree
Generate MRT

AI Insight

AI extracts a summary of this paper


Weibo:
These conclusions obscured the clinical benefits of corticosteroids on some subgroups of patients, those with severe symptoms, as the clinical effects might be related to the indication, the timing of intervention, the dose and duration of corticosteroids therapy9

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.

SIGNAL TRANSDUCTION AND TARGETED THERAPY, no. 1.0 (2020): 18-3

Cited by: 20|Views142
WOS

Abstract

Dear Editor, Since last December, the outbreak of 2019-nCoV in Wuhan has caused ever-increasing attention and public panic all over the world. Up to February 9, 2020, 40,171 patients had been diagnosed with 2019-nCoV infection, including 6484 (16.14%) severe cases and 908 deaths (2.27%). Compared to SARS and MERS, 2019-nCoV appears to be ...More

Code:

Data:

Introduction
  • Dear Editor, Since last December, the outbreak of 2019-nCoV in Wuhan has caused ever-increasing attention and public panic all over the world.
  • These conclusions obscured the clinical benefits of corticosteroids on some subgroups of patients, those with severe symptoms, as the clinical effects might be related to the indication, the timing of intervention, the dose and duration of corticosteroids therapy[9].
  • Salvage corticosteroids treatment for severe patients with advanced ARDS could alleviate the pulmonary fibrosis and prevent progressive pathological deterioration[11], which provides a good framework for explaining why some critical patients with SARS infection benefit from rescue corticosteroids therapy.
Highlights
  • Dear Editor, Since last December, the outbreak of 2019-nCoV in Wuhan has caused ever-increasing attention and public panic all over the world
  • These conclusions obscured the clinical benefits of corticosteroids on some subgroups of patients, those with severe symptoms, as the clinical effects might be related to the indication, the timing of intervention, the dose and duration of corticosteroids therapy[9]
  • Mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids[12]. All these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications according to the recommended guidelines
Results
  • Mortality benefit favored the severe HIN1-illness in the adjunctive treatment group with low dose of corticosteroids[12].
  • All these results strongly suggest that proper use of low-dose corticosteroids may bring survival advantages for critically ill patients with 2019-nCoV, but this treatment should be strictly performed on NCP patients with definite clinical indications according to the recommended guidelines.
  • CURRENT EVIDENCE: CLINICAL BENEFITS OF CORTICOSTEROIDS THERAPY FOR CRITICAL NCP PATIENTS Over the past month, we collaborated with front-line ICU physicians and firstly evaluated the efficacy of corticosteroids treatment for severe or fatal cases with 2019-nCoV infection in Wuhan.
  • Our clinical experience and available descriptive data from the therapeutic process of the first 15 critical NCP patients are prone to support corticosteroids treatment for specific subgroup of critically ill patients with 2019-nCoV.
  • PRECAUTIONS OF CORTICOSTEROIDS TREATMENT IN PATIENTS WITH 2019-NCOV There is no fixed clinical guideline for the use of corticosteroids in critically ill patients in ICU.
  • Corticosteroids should be avoided unless there are indications for moderate or severe ARDS, sepsis or septic shock, in part consistent with the recommended clinical guidance from World Health Organization (WHO).
  • Clinical adverse complications in SARS patients with corticosteroids treatment have been reported to be dose-related.
  • Lower dose and short duration of corticosteroids treatment, along with adverse drug reaction monitoring, would be more beneficial in clinical management of critical patients with 2019-nCoV.
  • We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival.
Conclusion
  • K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
  • Et al Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study.
  • Et al Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm[09] viral pneumonia.
Funding
  • There are still no specific antiviral medicines or vaccines recommended for 2019-nCoV infection
  • For patients with severe clinical manifestations, an effective clinical treatment scheme is of great importance
  • Pulse-dose therapy or long-term administration to high dose of corticosteroids in early stage were reported to be possibly harmful6–8. These conclusions obscured the clinical benefits of corticosteroids on some subgroups of patients, those with severe symptoms, as the clinical effects might be related to the indication, the timing of intervention, the dose and duration of corticosteroids therapy9
  • As documented in a series of randomized clinical trials , low or physiologic dose of corticosteroids treatment did not reduce mortality from septic shock caused by primary lung infections, but it could bring clinical benefits to secondary outcomes, such as earlier reversal of shock, shorter duration to exit from ICU and mechanical ventilation9,10
  • Does not suggest the use of corticosteroids for mild or early-stage ARDS, because early corticosteroids application could delay the clearance of virus and increase mortality risk, and corticosteroids are more likely to function on inflammation-mediated lung injury and interstitial fibro-proliferation at late-stage of ARDS11
Reference
  • regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.
    Findings
  • 1. National Health Commission of the People’s Republic of China. National Health org/licenses/by/4.0/. 2020 (in Chinese). http://www.nhc.gov.cn/xcs/yqtb/202002/167a0e01b2d24274 b03b2ca961107929.shtml (2020).
    Findings
Author
Wei Zhou
Wei Zhou
Yisi Liu
Yisi Liu
Dongdong Tian
Dongdong Tian
Cheng Wang
Cheng Wang
Sa Wang
Sa Wang
Jing Cheng
Jing Cheng
Ming Hu
Ming Hu
Minghao Fang
Minghao Fang
Your rating :
0

 

Tags
Comments
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn
小科